TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway
Joint Authors
Chen, Xide
Yan, Yuanli
Weng, Zhiyan
Chen, Chao
Lv, Miaoru
Lin, Qingwen
Du, Qiuxia
Shen, Ximei
Yang, Liyong
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-19
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Metabolic inflammatory damage, characterized by Toll-like receptor 4 (TLR4) signaling activation, is a major mechanism underlying lipotoxicity-induced β-cell damage.
The present study is aimed at determining whether G protein-coupled receptor 4 (GPR40) agonist can improve β-cell lipotoxicity-induced damage by inhibiting the TLR4-NF-κB pathway.
Lipotoxicity, inflammation-damaged β-cells, obese SD, and TLR4KO rat models were used in the study.
In vitro, TAK-875 inhibited the lipotoxicity- and LPS-induced β-cell apoptosis in a concentration-dependent manner, improved the insulin secretion, and inhibited the expression of TLR4 and NF-κB subunit P65.
Besides, silencing of TLR4 expression enhanced the protective effects of TAK-875, while TLR4 overexpression attenuated this protective effect.
Activation of TLR4 or NF-κB attenuated the antagonism of TAK-875 on PA-induced damage.
Moreover, the above process of TAK-875 was partially independent of GPR40 expression.
TAK-875 reduced the body weight and inflammatory factors, rebalanced the number and distribution of α or β-cells, inhibited the apoptosis of islet cells, and inhibited the expression of TLR4 and NF-κB subunit P65 in obese rats.
Further knockout of the rat TLR4 gene delayed the damage induced by the high-fat diet and synergy with the action of TAK-875.
These data suggest that GPR40 agonists antagonized the lipotoxicity β-cell damage by inhibiting the TLR4-NF-κB pathway.
American Psychological Association (APA)
Chen, Xide& Yan, Yuanli& Weng, Zhiyan& Chen, Chao& Lv, Miaoru& Lin, Qingwen…[et al.]. 2019. TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway. Journal of Diabetes Research،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1173051
Modern Language Association (MLA)
Chen, Xide…[et al.]. TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway. Journal of Diabetes Research No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1173051
American Medical Association (AMA)
Chen, Xide& Yan, Yuanli& Weng, Zhiyan& Chen, Chao& Lv, Miaoru& Lin, Qingwen…[et al.]. TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway. Journal of Diabetes Research. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1173051
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1173051